Market Place
Sourcing Support
Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals And Expands Pipeline
11 Oct 2023 //
PR NEWSWIRE
Important Information for Zynerba Stockholders to Tender Shares
04 Oct 2023 //
GLOBENEWSWIRE
Zynerba Stockholders Reminded to Tender Shares Before October 10, 2023
29 Sep 2023 //
GLOBENEWSWIRE
Harmony Announces Extension Of Tender Offer To Acquire Zynerba Pharma
27 Sep 2023 //
PR NEWSWIRE
Zynerba Presents Positive Data from Phase 2 Trial in 22q11.2 Deletion Syndrome
14 Sep 2023 //
GLOBENEWSWIRE
Harmony buys cannabidiol firm Zynerba in $200m deal
16 Aug 2023 //
PHARMAPHORUM
Harmony Biosciences To Acquire Zynerba Pharma For Up To $200 Mln
15 Aug 2023 //
NASDAQ
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
08 Aug 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
25 Jul 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
28 Jun 2023 //
GLOBENEWSWIRE
Zynerba to Present at the H.C. Wainwright 4th Annual Neuropsychiatry VC
20 Jun 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
13 Jun 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Podium and Poster Presentations
23 May 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Reports 1Q 2023 FYR Results and Operational Highlights
15 May 2023 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Presents Data on Zygel at the 55th Gatlinburg Conference
12 Apr 2023 //
GLOBENEWSWIRE
Zynerba Announces Poster Presentations at the 55th Gatlinburg Conference
05 Apr 2023 //
GLOBENEWSWIRE
Zynerba Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Zynerba Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
13 Mar 2023 //
GLOBENEWSWIRE
Zynerba to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Zynerba Pharma to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Zynerba Announces Update on RECONNECT, the Pivotal Phase 3 Trial
21 Dec 2022 //
GLOBENEWSWIRE
Zynerba Pharma Announces Positive Long-Term Data from Phase 2 INSPIRE Trial
05 Dec 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting
29 Nov 2022 //
GLOBENEWSWIRE
Zynerba Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel
28 Nov 2022 //
ZYNERBA
Zynerba Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygelâ„¢
28 Nov 2022 //
GLOBENEWSWIRE
Zynerba Announces EC Has Granted Orphan Drug Designation for Zygel
15 Nov 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel
02 Nov 2022 //
GLOBENEWSWIRE
Zynerba Announces Issuance of New U.S. Patent for Zygel
02 Nov 2022 //
ZYNERBA
Zynerba Pharmaceuticals Presents Positive Data from Ph2 INSPIRE Trial in 22q11.2
17 Oct 2022 //
GLOBENEWSWIRE
Zynerba Announces Poster Presentation at the (NORD) Rare Diseases
10 Oct 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
06 Oct 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Participate in the Cantor Neurology
29 Sep 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann
22 Sep 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE
08 Sep 2022 //
GLOBENEWSWIRE
Zynerba to Present In-Person at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Zynerba Announces Oral Presentation at The Society for the Study of (SSBP)
31 Aug 2022 //
PRESS RELEASE
Zynerba Pharmaceuticals Reports Q2 Financial Results and Operational Highlights
10 Aug 2022 //
GLOBENEWSWIRE
Zynerba Pharma to Present In Person at the Canaccord Genuity Conference
03 Aug 2022 //
GLOBENEWSWIRE
Zynerba Enters Into Equity Purchase Agreement for Up to $20 M
21 Jul 2022 //
GLOBENEWSWIRE
Zynerba Announces Positive Top Line Results from Open-Label PII Trial of Zygel
21 Jun 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Presents Data on Zygel at the ASCP
01 Jun 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at ASCP
24 May 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Conference
17 May 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel
11 May 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Podium Presentation at ISAR
09 May 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel
02 May 2022 //
GLOBENEWSWIRE
Zynerba Announces Presentation of Poster at the 2022 Society of Biological
21 Apr 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
05 Apr 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
22 Mar 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Reports Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Zynerba Pharma Announces EC Has Granted ODD for Zygel in Fragile X Syndrome
28 Feb 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals to Present at the SVB Leerink Conference
10 Feb 2022 //
GLOBENEWSWIRE
Zynerba Pharma nnounces Clinical Development Updates for FXS, ASD, 22q and DEE
04 Jan 2022 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific
21 Oct 2021 //
GLOBENEWSWIRE
Zynerba Pharmaceuticals Announces Presentation of(NORD) Rare Diseases
19 Oct 2021 //
GLOBENEWSWIRE
Zynerba Pharma Announces Presentation of Poster at the 2021 American Academy
08 Oct 2021 //
GLOBENEWSWIRE
Zynerba Pharma to Present at the Cantor Virtual Global Healthcare Conference
20 Sep 2021 //
GLOBENEWSWIRE
